These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 29290170)

  • 1. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
    Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
    J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.
    Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):712-713. PubMed ID: 29952702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 7. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
    Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
    J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case.
    Djatche LM; Goble JA; Chun G; Varga S
    J Manag Care Spec Pharm; 2018 Jan; 24(1):39-46. PubMed ID: 29290169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks.
    Agboola F; Lubinga S; Carlson J; Lin GA; Dreitlein WB; Pearson SD
    J Manag Care Spec Pharm; 2019 Feb; 25(2):143-148. PubMed ID: 30698087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma.
    Beinfeld M; Lee S; McQueen B; Fluetsch N; Pearson SD; Ollendorf DA
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1315-1320. PubMed ID: 34464215
    [No Abstract]   [Full Text] [Related]  

  • 14. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
    Synnott PG; McQueen RB; Ollendorf DA; Campbell JD; Pearson SD
    J Manag Care Spec Pharm; 2020 Jun; 26(6):782-785. PubMed ID: 32463783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis.
    Pandey R; Ollendorf DA; Fazioli K; Bloudek L; Carlson JJ; Pearson SD
    J Manag Care Spec Pharm; 2021 Mar; 27(3):405-410. PubMed ID: 33645245
    [No Abstract]   [Full Text] [Related]  

  • 16. The Effectiveness and Value of Treatments for Spinal Muscular Atrophy.
    Pearson SD; Thokala P; Stevenson M; Rind D
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1300-1306. PubMed ID: 31778620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma.
    Tice JA; Campbell JD; Synnott PG; Walsh JME; Kumar VM; Whittington M; Adair E; Rind D; Pearson SD
    J Manag Care Spec Pharm; 2019 May; 25(5):510-514. PubMed ID: 31039065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 20. The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.
    Mickle K; Lasser KE; Hoch JS; Cipriano LE; Dreitlein WB; Pearson SD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):10-15. PubMed ID: 30589627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.